PRIVA-SILDENAFIL TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
10-06-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
SILDENAFIL (SILDENAFIL CITRATE)
Inapatikana kutoka:
NORA PHARMA INC
ATC kanuni:
G04BE03
INN (Jina la Kimataifa):
SILDENAFIL
Kipimo:
100MG
Dawa fomu:
TABLET
Tungo:
SILDENAFIL (SILDENAFIL CITRATE) 100MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
4/8
Dawa ya aina:
Prescription
Eneo la matibabu:
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0136261003; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2023-07-01
Tabia za bidhaa
PRODUCT MONOGRAPH
PR
PRIVA-SILDENAFIL
Sildenafil Citrate Tablets
25 mg, 50 mg, and 100 mg
,
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
NORA PHARMA INC.
1565, Lionel-Boulet Boul.
Varennes, Quebec
J3X 1P7
Control #: 264224
Date
of
Preparation:
June 10, 2022
_Priva-SILDENAFIL_
Page 2 of 55
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.................................................
3
SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS...................................................................................................
3
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
7
DRUG
INTERACTIONS....................................................................................................
11
DOSAGE AND
ADMINISTRATION................................................................................
14
OVERDOSAGE..................................................................................................................
15
ACTION AND CLINICAL
PHARMACOLOGY..............................................................
16
STORAGE AND
STABILITY...........................................................................................
19
DOSAGE FORMS, COMPOSITION AND
PACKAGING...............................................
19
PART II: SCIENTIFIC
INFORMATION.........................................................................
20
PHARMACEUTICAL
INFORMATION...........................................................................
20
CLINICAL
TRIALS...........................................................................................................
21
DETAILED
PHARMACOLOGY.................................
Soma hati kamili
